Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization

European Journal of Ophthalmology

Volumn 22, Issue 2, 2012, Pages 210-215

  Matsuo, Misa ^a   Honda, Shigeru ^a   Matsumiya, Wataru ^a   Kusuhara, Sentaro ^a   Tsukahara, Yasutomo ^a   Negi, Akira ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti vascular endothelial growth factor; Myopic choroidal neovascularization; Photodynamic therapy

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GREATEST LINEAR DIMENSION; HUMAN; INTERMETHOD COMPARISON; MALE; MYOPIA; OUTCOME ASSESSMENT; OUTER NUCLEAR LAYER THICKNESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FOVEA; RETREATMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84862654167     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2011.7750     Document Type: Article

References (20)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103: 1241-4.
2. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110: 1297-305.
3. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001; 108: 841-52.
4. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003; 110: 667-73.
5. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009; 147: 94-100.
6. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147: 84-93.
7. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-5.
8. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91: 157-60.
9. Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007; 114: 2190-6.
10. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009; 93: 150-4.
11. Rensch F, Spandau UH, Schlichtenbrede F, et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008; 39: 182-5.
12. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008; 126: 941-5.
13. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148: 396-408.
14. Lammer J, Scholda C, Prünte C, Benesch T, Schmidt-Erfurth U, Bolz M. Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. Retina 2011; 31: 48-55.
15. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: twoyear results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207.
16. Saito MC, Shiragami C, Shiraga F, Kano M, Iida T. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 2010; 149: 472-81.
17. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006; 142: 95-104.
18. Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina 2007; 27: 713-23.
19. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30: 418-24.
20. Honda S, Kurimoto Y, Kagotani Y, Yamamoto H, Takagi H, Uenishi M, Hyogo Macular Disease Study Group. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol 2009; 53: 593-7.